Introduction
============

In Japan, one-third of all mortalities are cancer-related ([@b1-ol-05-02-0427]). The incidence of lung, colorectal and breast cancer is increasing in Japan as well as worldwide ([@b1-ol-05-02-0427]). Esophageal carcinoma has a lower incidence than other types of cancer, but 5-fluorouracil (5-FU) and cisplatin (CDDP)-based chemoradiotherapy results in moderately high response and survival rates relative to other types of cancer. In fact, the complete response and 5-year survival rates following 5-FU and CDDP-based chemoradiotherapy have been reported to be 58 and 29%, respectively, among Japanese esophageal carcinoma patients ([@b2-ol-05-02-0427]). However, chemotherapy remains ineffective in certain patients. Therefore, identifying the factors that affect sensitivity to 5-FU and CDDP is necessary for enhancing the clinical outcome of chemotherapy for esophageal carcinoma.

Certain factors affecting sensitivity to 5-FU or CDDP have previously been revealed, including the molecular mechanisms involved in the cellular kinetics and dynamics of 5-FU and CDDP. For example, overexpression of the ABC transporter superfamily C5 (ABCC5/MRP5) decreases cellular accumulation of 5-FU, resulting in resistance to 5-FU ([@b3-ol-05-02-0427]). In addition, dihydropyrimidine dehydrogenase (DPYD), a 5-FU metabolizing enzyme, has been correlated with clinical response to 5-FU-based chemotherapy among colon cancer patients ([@b4-ol-05-02-0427],[@b5-ol-05-02-0427]). The cytotoxic effects of CDDP are also attenuated by ERCC1, a DNA repair-related enzyme associated with restoration of DNA damage induced by chemotherapeutic agents or UV rays ([@b6-ol-05-02-0427]--[@b8-ol-05-02-0427]). However, there is little information concerning whether the levels of these molecules are predictive of sensitivity to 5-FU or CDDP in esophageal carcinoma.

In the present study, sensitivity to 5-FU and CDDP and mRNA levels of 35 genes, including drug transporters, DNA repair enzymes and metabolic enzymes, were evaluated in 5 human esophageal carcinoma cell lines. Based on these findings, factors affecting the sensitivity of esophageal carcinoma cells to 5-FU and CDDP were examined.

Materials and methods
=====================

Chemicals
---------

5-FU was obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). CDDP was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Gimeracil and MK571 were purchased from Toronto Research Chemicals, Inc. (Toronto, ON, Canada) and Cayman Chemical Company (Ann Arbor, MI, USA), respectively. 2-(4-Iodophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1) and 1-methoxy-5-methylphenazinium methylsulfate were purchased from Dojindo Laboratories (Kumamoto, Japan).

Cell culture
------------

The human esophageal adenocarcinoma cell line OE33 was purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Japan) and the squamous carcinoma cell lines KYSE30, KYSE70, KYSE140 and KYSE150 ([@b9-ol-05-02-0427]) were obtained from Health Science Research Resources Bank (Osaka, Japan). OE33 and the other cell lines were maintained in RPMI-1640 medium (Invitrogen Corp., Carlsbad, CA, USA) and Dulbecco's modified Eagle's medium (Invitrogen), respectively, supplemented with 10% heat-inactivated fetal bovine serum (lot no. 1335770 and 348777, Invitrogen). Cells were cultured in an atmosphere of 95% air and 5% CO~2~ at 37°C and subcultured every 3 or 4 days at a density of 1×10^6^ cells/25 cm^2^ culture flask. The number of passages for OE33, KYSE30, KYSE70, KYSE140 and KYSE150 cells was 15--25, 15--28, 15--26, 21--31 and 19--31, respectively.

Growth rate of esophageal carcinoma cell lines
----------------------------------------------

The growth rate of esophageal carcinoma cells was evaluated with a WST-1 assay utilizing succinate dehydrogenase activity. Cells were seeded onto a 96-well plate (Corning Inc., Corning, NY, USA) at a density of 5×10^3^ cells/well/100 *μ*l and cultured in an atmosphere of 95% air and 5% CO~2~ at 37°C. After 0, 6, 12, 18, 24, 36, 48, 72 and 96 h, the culture medium was exchanged for 110 *μ*l of medium containing WST-1 reagent solution (10 *μ*l WST-1 solution and 100 *μ*l culture medium), and 3 h later the absorbance was determined using a micro-plate reader at 450 nm with a reference wavelength of 620 nm (SpectraFluor™, Tecan Group Ltd., Männedorf, Switzerland). The doubling time for cell growth was calculated from the logarithmic phase of a growth curve ([@b10-ol-05-02-0427]) as follows: Doubling time = (t~1~ - t~0~) × log~10~2/(log~10~N~1~ - log~10~N~0~). N~0~ and N~1~ are the number of cells (% of day 0) at t~1~ and t~0~, respectively.

Growth inhibitory activity assay
--------------------------------

Cells were seeded onto 96-well plates (Corning Inc.) at a density of 5×10^3^ cells/well/100 *μ*l on day 0. After incubation for 24 h, the culture medium was exchanged for one containing 5-FU or CDDP at various concentrations (day 1). On day 4, a WST-1 assay was performed as described above.

The effects of gimeracil and MK571 on the growth inhibitory effects of 5-FU and CDDP were also evaluated by WST-1 assay. Cells were incubated for 24 h as described above and the culture medium was exchanged for one containing 5-FU or CDDP at various concentrations with or without gimeracil (100 *μ*M) or MK571 (50 *μ*M). Following incubation for 72 h at 37°C, the culture medium was replaced with a medium containing WST-1 and the absorbance was measured.

The 50% growth inhibitory concentrations (IC~50~) were calculated according to the sigmoid inhibitory effect model: E = E~max~ × \[1 - C^γ^/(C^γ^ + IC~50~^γ^)\], using the nonlinear least-squares fitting method (Solver, Microsoft^®^ Excel). E and E~max~ represent the surviving fraction (% of control) and its maximum, respectively. C and γ are the drug concentration in the medium and the sigmoidicity factor, respectively. Relative sensitivity was calculated as follows: Relative sensitivity = IC~50~ (without gimeracil or MK571)/IC~50~ (with gimeracil or MK571).

Real-time reverse transcription (RT)-PCR
----------------------------------------

The mRNA expression levels were measured by real-time RT-PCR. Cells were seeded at a density of 2×10^6^ cells/60 mm culture dish and 48 h later, total RNA was extracted from the cells with a GenEluteTM Mammalian Total RNA Miniprep kit (Sigma-Aldrich). Total RNA (1 *μ*g) was used for RT with a PrimeScriptTM RT reagent kit (Takara Bio, Inc., Shiga, Japan) and a thermal cycler (i-Cycler, Bio-Rad Laboratories, Inc., Hercules, CA, USA). The RT reaction was conducted in 40 *μ*l reaction buffer at 37°C for 15 min and terminated by heating at 85°C for 5 sec followed by cooling at 4°C.

Real-time PCR was performed with a 7500 Real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) and SYBR Premix Ex Taq™ (Takara Bio, Inc.). The primer sequences are shown in [Table I](#t1-ol-05-02-0427){ref-type="table"}. PCR was performed at 95°C for 10 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 34 sec. Dissociation was initiated at 95°C for 15 sec followed by 60°C for 1 min and 95°C for 15 sec. To compare the relative expression of target mRNA levels between the cell lines, the comparative Ct method was used, as previously described ([@b10-ol-05-02-0427]); β-actin (ACTB) was used as an internal standard. Samples were prepared in duplicate and three independent sample sets were analyzed.

Statistical analyses
--------------------

Data are shown as the mean ± standard deviation (SD). Comparisons between 2 and among 3 or more groups were performed with Student's unpaired t-test and repeated one-way analysis of variance (ANOVA) followed by Scheffe's F test, respectively. P\<0.05 (two-tailed) was considered to indicate a statistically significant result. The correlation analysis was performed using Pearson's correlation coefficient (r).

Results
=======

Growth rates of esophageal carcinoma cell lines
-----------------------------------------------

[Table II](#t2-ol-05-02-0427){ref-type="table"} shows the cell growth doubling times for the 5 esophageal carcinoma cell lines. Doubling times for the cells varied from 20 to 25 h, revealing a significant difference between lines. KYSE30 cells (20.1±1.41 h) had the shortest doubling time and OE33 cells (25.0±0.90 h) the longest.

Sensitivity of esophageal carcinoma cell lines to 5-FU and CDDP
---------------------------------------------------------------

The IC~50~ values for 5-FU were markedly different among the cell lines (0.524--30.2 *μ*M); the OE33 cells showed the highest sensitivity to 5-FU and the KYSE30 cells the lowest sensitivity ([Table III](#t3-ol-05-02-0427){ref-type="table"}). In the case of CDDP, the IC~50~ values were also substantially different among the cell lines (2.17--19.5 *μ*M). The rank order of sensitivity to CDDP was comparable to that for 5-FU.

Correlation analysis of factors affecting drug sensitivity
----------------------------------------------------------

The level of mRNA expression differed among the esophageal carcinoma cell lines ([Table IV](#t4-ol-05-02-0427){ref-type="table"}). The correlations between the IC~50~ values and the mRNA levels of the 35 different genes were analyzed ([Table V](#t5-ol-05-02-0427){ref-type="table"}). SLC22A3 mRNA was not detected in any cells, with the exception of the OE33 cell line. ABCC6 mRNA expression was not observed in KYSE30 and KYSE70 cells.

The mRNA levels of SLC22A2, SLC23A2, ABCB1 and Rad51 showed a strong negative correlation (r\<−0.7) with the IC~50~ values for 5-FU. ABCC2, MSH2 and DPYD were positively correlated with the IC~50~ values for 5-FU (r\>0.7; [Table V](#t5-ol-05-02-0427){ref-type="table"} and [Fig. 1](#f1-ol-05-02-0427){ref-type="fig"}). In the case of CDDP, a high positive correlation coefficient (r\>0.7) was found between the IC~50~ values and ABCC2, MSH2 and DPYD mRNA expression ([Table V](#t5-ol-05-02-0427){ref-type="table"} and [Fig. 2](#f2-ol-05-02-0427){ref-type="fig"}).

Effects of gimeracil and MK571 on sensitivity of esophageal carcinoma cell lines to 5-FU and CDDP
-------------------------------------------------------------------------------------------------

The sensitivity of KYSE30 cells to 5-FU was enhanced by gimeracil, but in the other cell lines gimeracil had no observable effect ([Table VI](#t6-ol-05-02-0427){ref-type="table"}). In addition, gimeracil showed a tendency to decrease the sensitivity of all the cell lines to CDDP.

MK571 had no observable effect on the KYSE30, KYSE140 and KYSE150 cells ([Table VII](#t7-ol-05-02-0427){ref-type="table"}). However, the sensitivity of KYSE70 cells to 5-FU was substantially accelerated by the presence of MK571, and the sensitivity of OE33 cells to 5-FU was markedly decreased. However, MK571 showed a tendency to decrease sensitivity to CDDP, with the exception of the KYSE30 and KYSE150 cell lines.

Discussion
==========

Combination chemotherapy with 5-FU and CDDP is known to be effective against esophageal carcinoma. However, it remains ineffective in certain patients, and the causes for this have not been clarified. The aim of the present study was to examine the factors affecting the sensitivity of esophageal carcinoma cells to 5-FU and CDDP.

The sensitivity of the 5 different esophageal carcinoma cell lines to 5-FU and CDDP differed ([Table III](#t3-ol-05-02-0427){ref-type="table"}). OE33, an adenocarcinoma cell line, showed a high sensitivity to 5-FU and CDDP, whereas the squamous cell carcinoma KYSE30 cells showed low sensitivity to 5-FU and CDDP. In addition, OE33 cells had the longest doubling time (an index of cell growth) of all the cell lines and KYSE30 cells the shortest ([Table II](#t2-ol-05-02-0427){ref-type="table"}), resulting in a trend for lower sensitivity to chemo-therapeutic agents among cells with higher growth activity. These findings suggest that sensitivity to 5-FU and CDDP was influenced by the growth activity of cells, although cytotoxic agents such as 5-FU and CDDP are known to be more toxic in cells with higher growth activity. In order to resolve this discrepancy, further studies concerning the correlation between cell growth and sensitivity to 5-FU or CDDP should be performed.

The correlations between sensitivity to 5-FU and CDDP and the mRNA levels of the 35 genes were then examined. The levels of target mRNA expression differed among the cell lines ([Table IV](#t4-ol-05-02-0427){ref-type="table"}). The mRNA levels of ABCC2, MSH2 and DPYD were positively correlated with the IC~50~ values of 5-FU (r\>0.7; [Fig. 1](#f1-ol-05-02-0427){ref-type="fig"} and [Table V](#t5-ol-05-02-0427){ref-type="table"}). By contrast, a negative correlation between the IC~50~ values of 5-FU and the mRNA levels of SLC22A2, SLC23A2, ABCB1 and Rad51 was observed. In the light of the biological roles of these genes, the negative correlation between SLC22A2 and SLC23A2 mRNA expression and sensitivity was considered to be noteworthy. SLC22A2 encodes an organic cation transporter which is responsible for cell uptake of various drugs, including CDDP ([@b11-ol-05-02-0427],[@b12-ol-05-02-0427]). A colon carcinoma cell line exhibiting resistance to 5-FU has been reported to show lower expression of SLC23A2 mRNA than its parent cells ([@b13-ol-05-02-0427]). ABCC2, MSH2 and DPYD are known to act in detoxifying mechanisms; they are an efflux transporter, DNA repair-related protein and metabolic enzyme, respectively. Although ABCB1 is a known efflux transporter that contributes to drug resistance, the cytotoxicity of 5-FU was not influenced by the expression of ABCB1 ([@b14-ol-05-02-0427]). In addition, the overexpression of DNA-repair related proteins, including Rad51, has been reported to contribute to resistance to DNA damaging agents ([@b15-ol-05-02-0427]). Although the present findings showing a negative correlation between IC~50~ values and ABCB1 and Rad51 mRNA expression levels conflict with previous findings, they may indicate that ABCB1 and Rad51 have no significant impact on sensitivity.

In the case of CDDP, a positive correlation (r\>0.7) between the IC~50~ values and the mRNA levels of ABCC2, MSH2 and DPYD was identified. The findings for ABCC2 and MSH2 are supported by their functions; the export of CDDP from cells ([@b16-ol-05-02-0427]) and repair of DNA damaged by CDDP ([@b17-ol-05-02-0427]), respectively ([Table V](#t5-ol-05-02-0427){ref-type="table"} and [Fig. 2](#f2-ol-05-02-0427){ref-type="fig"}). In addition, proliferating cell nuclear antigen-normalized mRNA expression of DPYD has previously been reported to be associated with sensitivity to CDDP in lung cancer tissues ([@b18-ol-05-02-0427]). Although the correlation between CDDP and DPYD has not been investigated in detail, these previous results may support the present findings. The mRNA levels of ABCC2, MSH2 and DPYD correlated well with sensitivity to both 5-FU and CDDP, suggesting that these are potent predictive factors for 5-FU and CDDP-based chemotherapy in esophageal carcinoma patients.

Finally, the roles of ABCC2 and DPYD in sensitivity to 5-FU and CDDP were examined, since the knock-down of MSH2 in SW460 and HeLa cells has been reported to have no influence on sensitivity to 5-FU ([@b19-ol-05-02-0427]). In the present study, 100 *μ*M gimeracil, which showed sufficient inhibition of DPYD ([@b20-ol-05-02-0427]), enhanced 5-FU sensitivity in the KYSE30 cell line ([Table VI](#t6-ol-05-02-0427){ref-type="table"}), which had the highest level of DPYD mRNA expression of all the cell lines tested ([Table IV](#t4-ol-05-02-0427){ref-type="table"}). The present findings support those of Ando *et al*([@b21-ol-05-02-0427]); that is, DPYD was a predictor of sensitivity to 5-FU. Apart from the correlation analysis, gimeracil decreased sensitivity to CDDP in all cell lines ([Table VI](#t6-ol-05-02-0427){ref-type="table"}), implying that DPYD activity may be required for the cytotoxic effect of CDDP. Further investigations are required to resolve this contradiction. The concomitant administration of 50 *μ*M MK571, a representative ABCC2 inhibitor ([@b22-ol-05-02-0427]), was found to decrease the sensitivity of OE33 and KYSE150 cells to 5-FU. In addition, the growth inhibitory activity of CDDP was decreased in KYSE30 and KYSE150 cell lines ([Table VII](#t7-ol-05-02-0427){ref-type="table"}). These findings conflict with the function of ABCC2 function as an efflux transporter, and further investigations are required to clarify this situation.

In conclusion, the mRNA levels of SLC22A2, SLC23A2, ABCB1, ABCC2, Rad51, MSH2 and DPYD were confirmed to be strongly correlated with the IC~50~ values for 5-FU, and those of ABCC2, MSH2 and DPYD were also confirmed to be strongly correlated with the IC~50~ values for CDDP. These genes have the potential to affect the sensitivity to 5-FU and CDDP. In addition, the inhibition of DPYD was suggested to affect the cytotoxicity of CDDP. These findings provide useful information for improving the clinical outcome of chemotherapy against esophageal carcinoma.
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![Correlation between IC~50~ values for 5-FU and mRNA expression levels in the esophageal carcinoma cell lines. The IC~50~ values for 5-FU were obtained from growth inhibition studies ([Table III](#t3-ol-05-02-0427){ref-type="table"}). The mRNA expression levels (2^−ΔCt^) in the cells were evaluated by real-time RT-PCR assay using SYBR^®^-Green. The threshold cycle (Ct) values were used to quantify the PCR product, and the relative expression level of the target gene was expressed as 2^−ΔCt^. The ΔCt was calculated by subtracting Ct (β-actin; as an internal standard) from Ct (target gene). 5-FU, 5-fluorouracil; RT, reverse transcription.](OL-05-02-0427-g00){#f1-ol-05-02-0427}

![Correlation between the IC~50~ values for CDDP and mRNA expression levels in the esophageal carcinoma cell lines. The IC~50~ values for CDDP were obtained from growth inhibition studies ([Table III](#t3-ol-05-02-0427){ref-type="table"}). The mRNA expression levels (2^−ΔCt^) in the cells were evaluated by real-time RT-PCR assay using SYBR^®^-Green. The threshold cycle (Ct) values were used to quantify the PCR product, and the relative expression level of the target gene was expressed as 2^−ΔCt^. ΔCt was calculated by subtracting Ct (β-actin; as an internal standard) from Ct (target gene). CDDP, cisplatin; RT, reverse transcription.](OL-05-02-0427-g01){#f2-ol-05-02-0427}

###### 

Sequences of oligonucleotide primers designed for real-time PCR.

  Function and gene   Forward (5′--3′)            Reverse (5′--3′)            Reference
  ------------------- --------------------------- --------------------------- -------------------------------------------------
  ACTB                TCATGAAGTGTGACGTGGACATC     TGCATCCTGTCGGCAATG          [@b10-ol-05-02-0427]
  Transport                                                                   
    SLC22A1           TCTTCCATCGTCACTGAGTTCAAC    AGAAGCCCGCATTCAAACAG        [@b10-ol-05-02-0427]
    SLC22A2           TCTACTCTGCCCTGGTTGAATTC     ATGCAGCCCAAGGGTAACG         [@b10-ol-05-02-0427]
    SLC22A3           TAGCCCCATTTCTGCTCTTTC       AGATGGATGCCAGGATACCAA       [@b10-ol-05-02-0427]
    SLC23A2           TCTTTGTGCTTGGATTTTCGAT      ACGTTCAACACTTGATCGATTC      [@b23-ol-05-02-0427]
    SLC31A1           ACAAGTCAGCATTCGCTACAATTC    TTGCAGGAGGTGAGGAAAGC        [@b9-ol-05-02-0427]
    ABCB1             TTCCTTCACCCAGGCAATG         ATGAGTTTATGTGCCACCAAGTAG    [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    ABCC1             CAGTGACCTCTGGTCCTTAAACAA    TTGGCGCATTCCTTCTTCC         [@b24-ol-05-02-0427]
    ABCC2             ACTTGTGACATCGGTAGCATGGA     AAGAGGCAGTTTGTGAGGGATGA     [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    ABCC3             GTCCGCAGAATGGACTTGAT        TCACCACTTGGGGATCATTT        [@b25-ol-05-02-0427]
    ABCC4             GCTCAGGTTGCCTATGTGCT        CGGTTACATTTCCTCCTCCA        [@b25-ol-05-02-0427]
    ABCC5             CGAAGGGTTGTGTGGATCTT        GTTTCACCATGAAGGCTGGT        [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    ABCC6             TGTCGCTCTTTGGAAAATCC        AGGAACACTGCGAAGCTCAT        [@b25-ol-05-02-0427]
    ABCG2             TGACGGTGAGAGAAAACTTAC       TGCCACTTTATCCAGACCT         [@b26-ol-05-02-0427]
    ATP7A             AGATACTGGGACACTGGAGAAA      AGGTCATCCCTTCCACTTTCA       [@b10-ol-05-02-0427]
    ATP7B             TGATTTATAACCTGGTTGGGATACC   ATGAGAGCACCACAGACACAGA      [@b10-ol-05-02-0427]
  DNA repair                                                                  
    ERCC1             TACAAGGCCTATGAGCAGAAACCA    TCTCTTGATGCGGCGATGAG        [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    ERCC2             CTGGAGGTGACCAAACTCATCTA     CCTGCTTCTCATAGAAGTTGAGC     [@b27-ol-05-02-0427]
    ERCC3             TATCCCAGGACACACAGGAAAT      TCACCTTGAAGCTATAACCTTGA     [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    XPA               TGCGGCGAGCAGTAAGAAG         TCATGGCCACACATAGTACAAGTC    [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    Rad51             TGGGAACTGCAACTCATCTGG       GCGCTCCTCTCTCCAGCAG         [@b28-ol-05-02-0427]
    BRCA1             ACAGCTGTGTGGTGCTTCTGTG      CATTGTCCTCTGTCCAGGCATC      [@b29-ol-05-02-0427]
    BRCA2             TGAAGAGCAGTTAAGAGCCTTGAA    ACGGTTGTGACATCCCTTGATAAA    [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    HMGB1             CAAGCGAACAGCAGGGTTAG        CAGATTGAGTCATTTGCTCCTCTTA   [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    HMGB2             TGAACATCGCCCAAAGATCA        TCAGACCACATTTCACCCAATT      [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    MLH1              GATTACCCCTTCTGATTGACA       ACTGAGGCTTTCAAAACA          [@b30-ol-05-02-0427]
    MSH2              CAGTATATTGGAGAATCGCA        AGGGCATTTGTTTCACC           [@b30-ol-05-02-0427]
    PMS2              AGTCAGCGTGCAGCAGTTATT       GACCATTTTGGCATACTCCTTCT     [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
    RPP25             AGAATGGTGGACAGTGGGATT       TACTTCAGGTGCTCTTCGTGAATG    [^a^](#tfn1-ol-05-02-0427){ref-type="table-fn"}
  Metabolism                                                                  
    GSTP1             CTGCGCATGCTGCTGGCAGATC      TTGGACTGGTACAGGGTGAGGTC     [@b31-ol-05-02-0427]
    GCLC              GGCAAGATACCTTTATGACCAGTT    TGCAGCACTCAAAGCCATAA        [@b32-ol-05-02-0427]
    GCLM              TGACTGCATTTGCTAAACAATTTGA   CGTGCGCTTGAATGTCAGG         [@b33-ol-05-02-0427]
    TYSM              GCCTCGGTGTGCCTTTCA          CCCGTGATGTGCGCAAT           [@b34-ol-05-02-0427]
    DPYD              AATGATTCGAAGAGCTTTTGAAGC    GTTCCCCGGATGATTCTGG         [@b35-ol-05-02-0427]
    UMPS              TAGTGTTTTGGAAACTGTTGAGGTT   CTTGCCTCCCTGCTCTCTGT        [@b36-ol-05-02-0427]
    MTHFR             CGGGTTAATTACCACCTTGTCAA     GCATTCGGCTGCAGTTCA          [@b36-ol-05-02-0427]

Primer sequences were designed using Primer Express^®^ software. ACTB, β-actin.

###### 

Doubling times of esophageal carcinoma cell lines.

  Cell line   Doubling time, mean ± SD (h)
  ----------- ------------------------------
  OE33        25.0±0.90
  KYSE30      20.1±1.41
  KYSE70      21.8±0.51
  KYSE140     23.3±1.07
  KYSE150     20.6±0.53

n=6.

###### 

IC~50~ values for 5-FU and CDDP in esophageal carcinoma cell lines.

            IC~50~ value, mean ± SD (*μ*M)   
  --------- -------------------------------- -----------
  OE33      0.524±0.08                       2.17±0.33
  KYSE30    30.2±8.29                        19.5±3.67
  KYSE70    13.1±13.3                        5.27±0.36
  KYSE140   1.88±0.38                        3.09±0.67
  KYSE150   4.75±1.46                        14.0±1.02

n=4. 5-FU, 5-fluorouracil; CDDP, cisplatin.

###### 

Expression levels of mRNA in esophageal carcinoma cell lines.

               Expression ratio, mean ± SD (2^−ΔCt^×10^−4^)                                          
  ------------ ---------------------------------------------- ------------ ------------ ------------ ------------
  Transport                                                                                          
    SLC22A1    0.11±0.03                                      0.07±0.02    0.01±0.003   0.03±0.02    0.12±0.07
    SLC22A2    0.49 ±0.15                                     0.16±0.03    0.23±0.03    0.87±0.45    0.47±0.36
    SLC22A3    36.3±9.24                                      ND           ND           ND           ND
    SLC23A2    76.1±13.8                                      36.6±6.39    59.8±4.66    61.1±43.8    92.9±64.0
    SLC31A1    125±26.6                                       131±10.2     179±23.4     252±135      244±147
    ABCB1      0.53±0.14                                      0.16±0.03    0.25±0.06    0.54±0.20    0.79±0.59
    ABCC1      74.7±11.3                                      37.0±3.83    246±32.9     123±75.6     67.8±36.6
    ABCC2      0.05±0.01                                      2.57±0.89    1.36±0.07    0.38±0.16    0.38±0.23
    ABCC3      80.5±15.1                                      10.2±2.64    60.7±8.62    40.6±23.3    123±86.7
    ABCC4      26.1±2.17                                      28.9±1.95    52.1±5.53    189±105      92.5±51.3
    ABCC5      9.06±1.30                                      62.14±17.0   65.38±8.60   22.92±10.6   26.76±19.2
    ABCC6      1.79±0.12                                      ND           ND           0.05±0.05    0.04±0.04
    ABCG2      6.25±1.29                                      4.64±0.21    1.66±0.34    2.47±0.69    33.1±18.3
    ATP7A      8.66±1.27                                      7.99±0.70    4.68±1.20    6.09±3.61    15.4±7.98
    ATP7B      1.91±0.25                                      1.89±0.73    2.21±0.47    5.72±4.77    3.37±2.69
  DNA repair                                                                                         
    ERCC1      219±66.1                                       143±35.8     96.3±13.2    241±131      296±175
    ERCC2      43.9±4.57                                      35.1±8.01    21.0±2.52    47.9±22.4    52.2±22.6
    ERCC3      82.3±11.5                                      79.3±19.4    57.4±6.31    134±97.9     185±104
    XPA        91.4±16.0                                      107±16.7     193±14.8     461±290      283±164
    Rad51      3.84±1.03                                      2.64±0.37    3.67±1.09    6.09±3.07    4.72±1.75
    BRCA1      90.5±15.6                                      61.1±2.46    65.3±4.56    188±116      151±78.8
    BRCA2      110±20.4                                       111±3.99     43.5±3.74    261±165      204±108
    HMGB1      35.2±7.29                                      35.9±1.84    51.4±3.98    79.9±47.8    37.6±19.1
    HMGB2      509±87.3                                       1340±150     1343±129     1980±947     1367±679
    MLH1       27.5±4.55                                      21.3±1.61    23.9±1.83    28.2±18.4    70.9±36.8
    MSH2       185±39.8                                       540±38.6     331±23.5     338±154      272±114
    PMS2       25.3±3.22                                      34.2±4.24    77.1±12.8    123±81.6     67.0±42.8
    RPP25      27.5±4.35                                      6.32±0.99    0.13±0.03    74.9±59.9    0.74±0.47
  Metabolism                                                                                         
    GSTP1      2444 ±425                                      2926±644     3421±380     5784±3549    7249±3978
    GCLC       5.21±0.51                                      3.87±1.15    45.0±4.30    10.8±4.41    9.05±5.39
    GCLM       8.38±2.61                                      31.34±4.30   75.1±10.8    33.0±15.4    32.1±22.2
    TYMS       54.0±11.6                                      163±3.10     2511±136     81.8±32.9    215.6±102
    DPYD       5.81±2.03                                      62.4±6.50    0.82±0.29    1.23±0.87    12.4±9.82
    UMPS       85.6±17.4                                      69.0±3.85    162±20.6     183±108      165±73.2
    MTHFR      5.78±1.85                                      10.0±2.39    18.6±2.72    25.6±23.2    23.7±15.3

ΔCt = Ct (target gene) - Ct (β-actin). ND, not detected; n=3.

###### 

Pearson's correlation coefficient between IC~50~ values for 5-FU or CDDP and mRNA expression level.

               Pearson's correlation coefficient (r)                  
  ------------ ------------------------------------------------------ --------
  Transport                                                           
    SLC22A1    −0.189                                                 0.333
    SLC22A2    −0.764                                                 −0.574
    SLC22A3    ND                                                     ND
    SLC23A2    −0.790                                                 −0.302
    SLC31A1    −0.477                                                 −0.132
    ABCB1      −0.788                                                 −0.215
    ABCC1      −0.150                                                 −0.530
    ABCC2      0.992[^b^](#tfn7-ol-05-02-0427){ref-type="table-fn"}   0.706
    ABCC3      −0.659                                                 −0.179
    ABCC4      −0.470                                                 −0.315
    ABCC5      0.573                                                  0.234
    ABCC6      ND                                                     ND
    ABCG2      −0.244                                                 0.398
    ATP7A      −0.199                                                 0.451
    ATP7B      −0.485                                                 −0.314
  DNA repair                                                          
    ERCC1      −0.638                                                 −0.041
    ERCC2      −0.533                                                 0.019
    ERCC3      −0.439                                                 0.187
    XPA        −0.463                                                 −0.284
    Rad51      −0.756                                                 −0.523
    BRCA1      −0.653                                                 −0.274
    BRCA2      −0.455                                                 −0.049
    HMGB1      −0.341                                                 −0.507
    HMGB2      0.010                                                  0.125
    MLH1       −0.369                                                 0.269
    MSH2       0.913[^a^](#tfn6-ol-05-02-0427){ref-type="table-fn"}   0.719
    PMS2       −0.363                                                 −0.365
    RPP25      −0.486                                                 −0.561
  Metabolism                                                          
    GSTP1      −0.401                                                 0.121
    GCLC       0.032                                                  −0.321
    GCLM       0.287                                                  −0.011
    TYMS       0.163                                                  −0.211
    DPYD       0.881                                                  0.863
    UMPS       −0.522                                                 −0.379
    MTHFR      −0.319                                                 −0.074

ND, not detected.

P\<0.05 and

P\<0.01 significant correlations between IC~50~ values and mRNA expression levels. 5-FU, 5-fluorouracil; CDDP, cisplatin.

###### 

Relative sensitivity of the esophageal carcinoma cell lines to 5-FU or CDDP with or without gimeracil.

            Relative sensitivity, mean ± SD (fold)   
  --------- ---------------------------------------- ------------
  OE33      1.10±0.37                                0.579±0.06
  KYSE30    2.30±0.13                                0.710±0.03
  KYSE70    1.16±0.19                                0.687±0.05
  KYSE140   0.989±0.15                               0.691±0.10
  KYSE150   1.19±0.16                                0.788±0.25

Relative sensitivity, the ratio of IC~50~ value for 5-FU or CDDP without gimeracil to those with gimeracil (n=4). Gimeracil, 100 *μ*M. 5-FU, 5-fluorouracil; CDDP, cisplatin.

###### 

Relative sensitivity of the esophageal carcinoma cell lines to 5-FU or CDDP with or without MK571.

            Relative sensitivity, mean ± SD (fold)   
  --------- ---------------------------------------- ------------
  OE33      0.0680±0.01                              0.852±0.28
  KYSE30    0.961±0.06                               0.974±0.09
  KYSE70    2.36±1.36                                0.617±0.06
  KYSE140   0.813±0.16                               0.803±0.04
  KYSE150   0.731±0.11                               1.08±0.26

Relative sensitivity, the ratio of IC~50~ values for 5-FU or CDDP without MK571 to those with MK571 (n=4). MK571, 50 *μ*M. 5-FU, 5-fluorouracil; CDDP, cisplatin.
